PD-1 trial stopped early

http://news.bms.com/press-release/checkmate-017-phase-3-study-opdivo-nivolumab-compared-docetaxel-patients-second-line-s

Superior preliminary data for ns lung ca. FDA should approve soon. Renal cell cancer trial preliminary data PD-1 Opdivo vs Affinitor Everolimus should come summer 2015, hopefully and hopefully will be superior and quickly FDA approved. 

http://www.marketwatch.com/story/checkmate--017-a-phase-3-study-of-opdivo-nivolumab-compared-to-docetaxel-in-patients-with-second-line-squamous-cell-non-small-cell-lung-cancer-stopped-early-2015-01-11